Peripheral Blood Signature of Vasodilator-Responsive Pulmonary Arterial Hypertension
暂无分享,去创建一个
S. Rich | S. Archer | J. Newman | Chang Yu | E. Austin | H. Nian | A. Hemnes | L. Wheeler | I. Robbins | Niki L. Penner | Mitchell Funke | A. Trammell | J. West | James West
[1] J. Newman,et al. Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function , 2013, Pulmonary circulation.
[2] Roderick C Deaño,et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. , 2013, JAMA internal medicine.
[3] J. Newman,et al. Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. , 2013, JACC. Heart failure.
[4] D. Harrison,et al. Dysfunctional resident lung mesenchymal stem cells contribute to pulmonary microvascular remodeling , 2013, Pulmonary circulation.
[5] L. Gleaves,et al. A potential role for insulin resistance in experimental pulmonary hypertension , 2012, European Respiratory Journal.
[6] J. Harral,et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[7] S. Menon,et al. Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression , 2011, Pulmonary circulation.
[8] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[9] T. Rice,et al. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[10] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[11] G. Raskob,et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.
[12] Marisa Wong Medina,et al. Pharmacogenomic Discovery Using Cell-Based Models , 2009, Pharmacological Reviews.
[13] H. Champion,et al. Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography , 2009, International journal of clinical practice. Supplement.
[14] J. Newman,et al. Association of the metabolic syndrome with pulmonary venous hypertension. , 2009, Chest.
[15] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[16] N. Weissmann,et al. Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[17] J. Cogan,et al. Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetrance , 2008, BMC Medical Genomics.
[18] H. Calkins,et al. Mechanisms of Disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy , 2008, Nature Clinical Practice Cardiovascular Medicine.
[19] G. Hansmann,et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. , 2008, The Journal of clinical investigation.
[20] M. Maitland,et al. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. , 2008, American journal of physiology. Heart and circulatory physiology.
[21] Michael D. Schneider,et al. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. , 2006, The Journal of clinical investigation.
[22] Hugh Calkins,et al. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2006, American journal of human genetics.
[23] S. Archer,et al. An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.
[24] Eric W. Glissmeyer,et al. Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension , 2006, Circulation.
[25] M. Humbert,et al. Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.
[26] G. Danieli,et al. Mutations in Desmoglein-2 Gene Are Associated With Arrhythmogenic Right Ventricular Cardiomyopathy , 2006, Circulation.
[27] D. Peterson,et al. Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction , 2005, Circulation.
[28] M. Humbert,et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.
[29] J. Pessin,et al. Lipid Raft targeting of the TC10 amino terminal domain is responsible for disruption of adipocyte cortical actin. , 2003, Molecular biology of the cell.
[30] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[31] B. Brundage,et al. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.
[32] W. Chung,et al. A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[33] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[34] J. Kartenbeck,et al. Desmosomes and hemidesmosomes: constitutive molecular components. , 1990, Annual review of cell biology.